Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Therapy

Thalidomide for the treatment of patients with myelodysplastic syndromes

Leukemia volume 16, pages 1–6 (2002)Cite this article

Abstract

We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Willman CL, Barrett AJ, Saunthararajah Y, Hellström-Lindberg E . Achievements in understanding and treatment of myelodysplastic syndromes Hematology American Society of Hematology: Washington 2000 pp 110–132

    Google Scholar 

  2. Zwingenberger K, Wnendt S . Immunmodulation by thalidomide: systematic review of the literature and of unpublished results J Inflamm 1995–1996 46: 177–211

    CAS  PubMed  Google Scholar 

  3. Verbon A, Juffermans NP, Speelman P, van Deventer SJH, Ten Berge IJM, Guchelaar HJ, van der Poll T . A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans Antimicrobial agentschemother 2000 44: 2286–2290

    Article  CAS  Google Scholar 

  4. Haslett PAJ, Corrall LG, Albert M, Kaplan G . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset J Exp Med 1998 187: 1885–1892

    Article  CAS  Google Scholar 

  5. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW . The immunosuppressive drug thalidomide induces T helper cell type 2 (Th 2) and concomitantly inhibits Th 1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures Clin Exp Immunol 1995 99: 160–167

    Article  CAS  Google Scholar 

  6. D'Amato RJ, Loughnan MS, Flynn E, Folkman J . Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 1994 91: 4082–4085

    Article  CAS  Google Scholar 

  7. Bauer KS, Dixon SC, Figg WG . Inhibition of angiogenesis bythalidomide requires metabolic activation, which is species-dependent Biochem Pharmacol 1998 55: 1827–1834

    Article  CAS  Google Scholar 

  8. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B . Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 1999 341: 1565–1571

    Article  CAS  Google Scholar 

  9. Blade J, Esteve J . Treatment approaches for relapsing and refractory multiple myeloma Acta Oncol 2000 39: 843–847

    Article  CAS  Google Scholar 

  10. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O'Brien S, Keating M, Freireich E, Albitar M . Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood 2000 96: 2240–2245

    CAS  PubMed  Google Scholar 

  11. Pruneri G, Bertolini F, Soglio D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F . Angiogenesis in myelodysplastic syndromes Br J Cancer 1999 81: 1398–1401

    Article  CAS  Google Scholar 

  12. Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000 37: 15–29

    Article  CAS  Google Scholar 

  13. Smith MA, Smith JG . The occurrence, subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study Leuk Res 1991 15: 597–601

    Article  CAS  Google Scholar 

  14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C . Proposals for the classification of the myelodysplastic syndromes Br J Haematol 1982 51: 189–199

    Article  CAS  Google Scholar 

  15. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J . International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997 89: 2079–2088

    CAS  PubMed  Google Scholar 

  16. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Löwenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL . Report of an international working group standardize response criteria for myelodysplastic syndromes Blood 2000 96: 3671–3674

    CAS  PubMed  Google Scholar 

  17. Dourado CMC, Seixas-Silva JA, Besa EC . Response to thalidomide in 9 patients with myelodysplastic syndromes: a promising treatment for early or post-chemotherapy in late forms of MDS Blood 2000 96: 260b

    Google Scholar 

  18. Mundle S, Zorat F, Shetty V, Allampallam K, Alvi S, Lisak L, Little L, Dean L, Nascimben F, Ekbal M, DuRandt M, Broderick E, Venugopal P, Raza A . Biologic determinents of clinical response to thalidomide in myelodysplasia Blood 2000 96: 146a

    Google Scholar 

  19. Raza A . Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes Microsc Res Tech 2000 50: 229–235

    Article  CAS  Google Scholar 

  20. Raza A, Lisak L, Little L, Ekbal M, duRandt M, Ali E, Nascimben F, Tareen M, Venugopal P . Thalidomide as single agent or in combination with topotecan, pentoxifylline and/or enbrel in myelodysplastic syndromes (MDS) Blood 2000 96: 146a

    Google Scholar 

  21. Thomas DA, Aguayo A, Estey E, Albitar M, O'Brien S, Giles FJ, Beran M, Cortes J, Zeldis J, Keating MJ, Barlogie B, Kantarjian HM . Thalidomide as anti-angiogenesis therapy (RX) in refractory or relapsed leukemias Blood 1999 94: 611a

    Google Scholar 

  22. Nogueira A, Neubert R, Helge H, Neubert D . Thalidomide and the immune system 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells Life Sci 1994 55: 77–92

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr K Zwingenberger, Grünenthal GmbH, for providing the study medication.

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany

    C Strupp, U Germing, M Aivado, E Misgeld, R Haas & N Gattermann

Authors
  1. C Strupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U Germing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Aivado
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Misgeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Gattermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strupp, C., Germing, U., Aivado, M. et al. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16, 1–6 (2002). https://doi.org/10.1038/sj.leu.2402330

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402330

Keywords

This article is cited by

Search

Advanced search

Quick links